Loading...
Dare to Lead: Public health and company wealth
Citations
Altmetric:
Titre
Publication date
2001-01-01
Document type
Briefing paper
Pages
36
Author(s)
Advisors
Editor(s)
Other Contributors
Affiliation
ePub Date
Submitted date
Subject
Local subject classification
MeSH
Keywords
Country
Collections
Files
Loading...
English paper
Adobe PDF, 1.68 MB
Loading...
French paper
Adobe PDF, 380.62 KB
Description
This is the first in a series of Oxfam Briefings analysing the impact on human development of transnational corporations (TNCs). It reviews the role of the newly formed GlaxoSmithKline (GSK) and outlines three challenges facing GSK and other global pharmaceutical companies wishing to increase poor people's access to medicines. First, how to ensure that changes in global intellectual property (IP) protection do not further increase the prices of medicines in developing countries. Secondly, the acute need for research and development (R&D) into diseases associated with poverty. And thirdly, the need to curb corporate marketing and lobbying activities when they run counter to the public interest.
Language
English
French
French
Other Titles
Abstract
Citation
Publisher(s)
Journal
Journal Theme
Volume
Issue
Research Unit
DOI
Table of contents
Series
ISSN
EISSN
ISBN
978-1-84814-128-5